Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer.

Abstract

Breast cancer (BC) is one of the most common cancers diagnosed and the leading cause of cancer-related death in women. Although there are first-line treatments for BC, drug resistances and adverse events have been reported. Given the incidence of BC keeps increasing, seeking novel therapeutics is urgently needed. Fucoxanthin (Fx) is a dietary carotenoid commonly found in seaweeds and diatoms. Both in vitro and in vivo studies show that Fx and its deacetylated metabolite fucoxanthinol (Fxol) inhibit and prevent BC growth. The NF-κB signaling pathway is considered the major pathway contributing to the anti-proliferation, anti-angiogenesis and pro-apoptotic effects of Fx and Fxol. Other signaling molecules such as MAPK, MMP2/9, CYP and ROS are also involved in the anti-cancer effects by regulating the tumor microenvironment, cancer metastasis, carcinogen metabolism and oxidation. Besides, Fx also possesses anti-obesity effects by regulating UCP1 levels and lipid metabolism, which may help to reduce BC risk. More importantly, mounting evidence demonstrates that Fx overcomes drug resistance. This review aims to give an updated summary of the anti-cancer effects of Fx and summarize the underlying mechanisms of action, which will provide novel strategies for the development of Fx as an anti-cancer therapeutic agent.

• Authors: Tsz-Ying Lau, Hiu-Yee Kwan
• Journal: Marine drugs (Mar Drugs) Vol. 20 Issue 6 (May 30 2022) ISSN: 1660-3397 [Electronic] Switzerland
• PMID: 35736173 (Publication Type: Journal Article, Review)

Chemical References

• NF-kappa B
• Xanthophylls
• fucoxanthin

Topics

• Breast Neoplasms (drug therapy)
• Female
• Humans
• NF-kappa B (metabolism)
• Signal Transduction
• Tumor Microenvironment
• Xanthophylls (pharmacology, therapeutic use)